Clinical Trial Update: A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes. [Phase 2]

View source ↗

Summary

A Phase 2 dose-titration study of GK Activator (2) in patients with type 2 diabetes has completed, sponsored by Hoffmann-La Roche.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• GK Activator (2)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Diabetes Mellitus Type 2 | Phase 2 | Status: COMPLETED